Fluidigm Corp
F:FLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (23.5), the stock would be worth €-8.83 (1 184% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.2 | €0.82 |
0%
|
| Industry Average | 23.5 | €-8.83 |
-1 184%
|
| Country Average | 14.4 | €-5.4 |
-762%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
F
|
Fluidigm Corp
F:FLB
|
314.9m EUR | -2.2 | -4.8 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 190.7 | 4 155.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
194.1B USD | 20 | 29 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137B USD | 19.3 | 37.9 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.5B CHF | 17.7 | -131.4 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
315.3B CNY | 17.3 | 16.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.4B USD | 19 | 25.9 | |
| US |
|
Waters Corp
NYSE:WAT
|
31.3B USD | 31.4 | 48.7 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.2B USD | 12 | 21.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD | 22.4 | 30.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
